ARTICLE | Finance
Holiday cheer
VCs getting solid return in Takeda takeout of oncology play Intellikine
January 2, 2012 8:00 AM UTC
Christmas came in the form of a nearly 5x return for investors in Intellikine Inc., as Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) is buying the Phase I cancer company for $190 million up front.
Intellikine was founded in 2007 and raised $41 million in two venture rounds. Investors include Novartis Bioventures; U.S. Venture Partners; Biogen Idec Inc. (NASDAQ:BIIB); FinTech Global Capital; Abingworth; CMEA; and Sofinnova Ventures...